Creating a synthetic human genome has the possibilities of improving human healthspans, but it also comes with extremely ...

The sudden rise of Oropouche disease startled scientists and health officials. Since its discovery, there have only been around 500,000 known cases. By contrast, there are upward of 400 million dengue ...

A new Trump presidency and the Ukraine war have pushed Germany to change its constitution to spend more on its military.

CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at German Cancer Research Center (DKFZ) and its spin-out company, TcellTech ...

Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation.

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a market size of USD 24.6 Billion by 2032 growing at a CAGR of 18.5% from ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected to reach around USD 46.02 billion by 2034, growing at a CAGR of 20.4% ...

The global viral vector and plasmid DNA manufacturing market size was calculated at US$ 7.26 billion in 2024 and is projected to reach around US$ 43.04 billion by 2034, expanding at a compound annual ...

Touchlight’s dbDNA™ helps research and development of Zika vaccine Touchlight (London, UK), a CDMO specializing in enzymatic DNA production, is supplying the University of Nottingham (UK) with its ...